A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. - sprookjes - yvandenbroek - TriplyDB

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

http://www.wikidata.org/entity/Q33387432

about

Critical appraisal of trastuzumab in treatment of advanced stomach cancer New advances in targeted gastric cancer treatment Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy Targeting receptor tyrosine kinases in gastric cancer Molecular targeted therapy for the treatment of gastric cancer Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Targeted therapies for gastric cancer: current status.Molecular targeting to treat gastric cancer.Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Targeted therapy in gastroesophageal cancers: past, present and future.A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.Targeted therapies in gastric cancer and future perspectives.A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.The progress of targeted therapy in advanced gastric cancer Anti-HER agents in gastric cancer: from bench to bedside.Evolving standards of care in advanced gastric cancer.Molecular targeted agents for gastric and gastroesophageal junction cancer.Current status of targeted therapies in advanced gastric cancer.Targeted therapy for gastric cancer.Novel targeted agents for gastric cancer.Targeted therapy for gastric cancer--current status.Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?Metastatic gastric cancer treatment: a little slow but worthy progress.Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.Recent advances and future trends in the targeted therapy of metastatic gastric cancer.Investigational therapies targeting the ErbB family in oesophagogastric cancer.Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer.The role of targeted therapy for gastrointestinal tumors.Clinical management of advanced gastric cancer: the role of new molecular drugs.Advancing pharmacological treatment options for advanced gastric cancer.Current advances in targeted therapies for metastatic gastric cancer: improving patient care.Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?Advanced gastric adenocarcinoma: optimizing therapy options.Long-term survival in an advanced gastric cancer patient treated with cetuximab in association with FOLFIRI: a case report.Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma.Novel Systemic Therapies for Advanced Gastric Cancer.Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial.Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer.

P2860

Q24604411-56160A58-800D-4B79-BB66-7EABF6CB1B9B Q26738548-2EA4A822-AA3A-41F4-8DFF-01B8E800A130 Q26798420-93875C38-FB37-4CC5-9FFA-BB7FF708C4C8 Q27013050-462B870A-F6F1-4F54-93BF-3294F3B4A786 Q28072433-B4ECB37F-6F92-48BF-A185-DBF5781D3E10 Q33430940-4351AAE5-BB67-499E-9422-1AB8A26105C0 Q34205672-90DD6C8C-8AEE-451D-9B7D-FDC0EE5ECDBF Q34326593-12339C35-3DA3-429B-8EBA-4FA4FF366474 Q35554809-BC31E378-25A5-4BD2-9225-646436C7AD48 Q35863874-B5AB09D5-F3A2-45DF-981E-FAB0A9A731E7 Q36294579-FE68465B-FA41-4135-ACC0-C0DF6248EC73 Q36306554-A44C82A9-91A3-4306-896D-C37134A6A80D Q36471685-EE3248C0-C3E5-40C6-A20B-AB7853B76EA8 Q37240838-633C48F0-8A89-4BF9-9EBD-17CBFD4A77C4 Q37427269-8F39B5B5-267C-42A3-AE27-C9244F2CC808 Q37885725-F56267ED-4933-431E-B133-97A91CA0CB39 Q37960206-47B68127-5E2B-4E29-9CA9-7874E159D451 Q37962816-B9C79C93-087A-4446-B022-8FEBC5446771 Q37996448-12E3D397-2B92-4411-8D1F-76A30CB9A8B5 Q38007119-0A3DB19F-BB9F-459D-B5DC-73ACA7308B16 Q38019657-A46A09DD-4079-4170-90EE-3C834EA777AD Q38019898-569A6B90-5ACF-4787-B681-D859A9287A74 Q38074157-A1304451-430E-46B1-BAF5-9C2C24EF7FFC Q38075499-7222F785-25DB-4D1A-A877-5E37B0E9688D Q38161727-C825D9C0-A45F-452E-823D-93EF38F31157 Q38199128-10F2209C-D1CD-44CA-B807-CCE6DF3D7762 Q38221886-2E109F31-0239-49F2-9A66-3E35672AC919 Q38222270-63752A0D-17E4-4D2B-ABB9-5CEF710302A3 Q38222585-4A113126-C071-4D3A-A274-5AC51F26DC8E Q38263841-D18A9A97-A582-40B9-B040-EDA1C12B239D Q38584644-6870DF29-16C6-4DBC-9E25-AB770110352F Q38720829-DFA81331-B504-416E-BBF1-402AEF2E82E6 Q38939088-AB46BD23-63E2-41D9-B3F2-929704106AA7 Q39091817-BC3E17D8-62ED-42A3-931E-AC5D53F47633 Q41894890-88AFB601-0F0A-42EB-9BDF-D04F462F96FD Q49961144-230064BF-1B4E-4E2E-A21D-E6160ED032BD Q52599496-B4531A86-1BE6-4398-8A4A-37F30F7D5ABA Q54321114-57A08C9D-4BC5-424F-888D-A9B9DEA76D48 Q54578867-70C93960-CDFC-4EE2-8F4D-66614C83BB53 Q55026328-91DAC029-118C-404D-8356-5EEB12069B51

P2860

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

http://www.wikidata.org/entity/Q33387432

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A prospective phase II study o ...... rrent advanced gastric cancer.

@ast

A prospective phase II study o ...... rrent advanced gastric cancer.

@en

type

label

A prospective phase II study o ...... rrent advanced gastric cancer.

@ast

A prospective phase II study o ...... rrent advanced gastric cancer.

@en

prefLabel

A prospective phase II study o ...... rrent advanced gastric cancer.

@ast

A prospective phase II study o ...... rrent advanced gastric cancer.

@en

P1433

Q33387432-0B9EC703-7DDF-43F2-A4B0-62053747F16D

P1476

Q33387432-B3CE68E8-37F9-4370-ABCA-01EA6B481059

P2093

Q33387432-10BDFC46-A15A-448E-AAD9-0350B534345F

Q33387432-5A51EAF4-483F-4D38-933C-EE62FC570749

Q33387432-613CF2F5-C2E1-4D8E-857A-F0A98BF04780

Q33387432-7D5DA1AF-7001-478F-9F85-809B435CA058

Q33387432-93A52E6A-73A5-4C12-9661-30E671F23F3D

Q33387432-A2FDC288-6564-49B5-B1DB-6729BE56F325

Q33387432-ABF98D7D-6C68-410A-8864-B605EDC706A6

Q33387432-D5B8807C-6C63-4C14-AA9A-6F6FA2188C98

Q33387432-E1A9EECE-4188-4B8C-AE8D-DA12110209D7

Q33387432-F98526AB-CABF-4051-9EBD-96ACCF357895

P2860

Q33387432-008724BA-CBB4-480D-BA8C-86B99223109C

Q33387432-00C724B0-B77C-452C-805A-29EF1773E70A

Q33387432-098BCB43-B9D8-42CF-B2B3-7A5E818D4F8C

Q33387432-0E373094-64A8-4D3B-926F-AE0BA4C2C438

Q33387432-115DBE23-83EE-4CA9-8BB5-A97F0477CF82

Q33387432-27A1F978-1908-48B8-97BF-C18F1A32A2F4

Q33387432-2F212085-EEB9-44FA-AFAF-326892E6A697

Q33387432-469FCBA8-D35F-431E-8C9B-8E97F12FEE24

Q33387432-49C6AEB4-A2DD-4DC0-969F-2E1248374991

Q33387432-4D7F8624-1845-43C3-A1D3-DB3B8914FCCA

P2888

Q33387432-4B2509F2-F033-45F3-8C9B-00A9C787B336

P304

Q33387432-E4E820C7-4F98-4966-AA66-5D0D149D1C4A

P31

Q33387432-12D6F308-3AB9-4DCA-B0D9-22C69B8F28EE

P356

Q33387432-853061DC-D246-450C-9B61-90BA6FB767B6

P433

Q33387432-BDDC2214-90DB-4518-A53E-7ABF41C51375

P478

Q33387432-D6CC2EFC-F548-4DCB-B79A-D737D90DEC20

P577

Q33387432-08D57AA5-7CFD-4858-A6CD-04567F4BAB93

P6179

Q33387432-A4789B96-F7A0-42B6-9AD8-35186F0DBA99

P698

Q33387432-9098F745-24CB-4D2D-B3E9-56337859E890

P921

Q33387432-98414665-D673-4990-8D4D-20C03CB0741A

P356

S10637-009-9363-0

P1433

Investigational New Drugs

P1476

A prospective phase II study o ...... rrent advanced gastric cancer.

@en

P2093

Baek-Yeol Ryoo

http://www.w3.org/2001/XMLSchema#string

Chul Kim

http://www.w3.org/2001/XMLSchema#string

Heung Moon Chang

http://www.w3.org/2001/XMLSchema#string

Ho Young Lim

http://www.w3.org/2001/XMLSchema#string

Hye Jin Kang

http://www.w3.org/2001/XMLSchema#string

Jae-Lyun Lee

http://www.w3.org/2001/XMLSchema#string

Min-Hee Ryu

http://www.w3.org/2001/XMLSchema#string

Tae Won Kim

http://www.w3.org/2001/XMLSchema#string

Yoon-Koo Kang

http://www.w3.org/2001/XMLSchema#string

Young Suk Park

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Cetuximab for the treatment of colorectal cancer.

Global cancer statistics, 2002

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.

Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer.

P2888

s10637-009-9363-0

P304

366-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-009-9363-0

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1046585078

http://www.w3.org/2001/XMLSchema#string

P698

19997960

http://www.w3.org/2001/XMLSchema#string

P921